Market Place
Sourcing Support
Pharvaris Reports 2024 Financial Results and Business Update
07 Apr 2025 //
GLOBENEWSWIRE
Pharvaris: Orphan Designation Granted to Deucrictibant by EU
01 Apr 2025 //
GLOBENEWSWIRE
Pharvaris To Present HAE Treatment Data At HAEi Workshop
03 Oct 2024 //
GLOBENEWSWIRE
Pharvaris Presents Deucrictibant Data At Bradykinin Symposium
05 Sep 2024 //
GLOBENEWSWIRE
Pharvaris Provides Business Update And Expands Program
05 Sep 2024 //
GLOBENEWSWIRE
Pharvaris: Deucrictibant Data Highlights At Recent Conferences
04 Jun 2024 //
GLOBENEWSWIRE
Pharvaris to Present Deucrictibant Data at the CIIC Spring 2024 Conference
04 Apr 2024 //
GLOBENEWSWIRE
Pharvaris Announces Phase 3 Clinical Study Design
18 Mar 2024 //
GLOBENEWSWIRE
Positive Results from Phase 2 of Deucrictibant for HAE Attacks to be Presented
22 Feb 2024 //
GLOBENEWSWIRE
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant
22 Jan 2024 //
GLOBENEWSWIRE
Pharvaris Announces Positive Top-line Phase 2 Data of Deucrictibant
06 Dec 2023 //
GLOBENEWSWIRE
Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant
26 Jun 2023 //
GLOBENEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.